Dear Secretary Becerra and Administrator Brooks-LaSure:
"As you consider policies to reduce prescription drug spending, we respectfully ask that you enact policies that would increase the uptake of biosimilars, specifically by reducing or eliminating out-of-pocket costs for Medicare Part B patients taking a biosimilar through a zero-co-pay policy. We were pleased to see President Biden’s Executive Order on Promoting Competition in the American Economy showed substantial support for biosimilars, directing HHS to increase support for biosimilars and generic drugs."
Read the Full Letter
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your US representatives or European Members of Parliament through our online platform. Take action and make a difference today.
